Special report by epic research 8 jan 2013


Published on

Epic Research is a leading financial services provider with presence in Indian and other global capital markets. Provides Stock Tips, Forex Tips, Commodity Tips, MCX Tips, Equity Tips, Tips, Intraday Tips, NSE Tips, BSE Tips, COMEX Tips, PCG Pack and NCDEX Tips. We provide services in equity, commodity and Forex market.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Special report by epic research 8 jan 2013

  1. 1. 8TH January 2013DAILY CHARTIST VIEW
  2. 2. HIGHLIGHTSA  Highlights  Nifty showed bearish trend on Monday.  Nifty Future ended 31.95 points down at 6016.05  Bharti Airtel sell call we recommended executed today and is currently trading at cost  Tata Chemicals sell call remained unexecuted  Investors’ are advised to hold position in Bharti Airtel sell call and take position in the fresh call provided below.  Sell Bharti Airtel futures below 328.45 for targets 327/325  Sell Auro Pharma futures below 200 for targets 198/195  Past Performance:  Allahabad bank buy call hit both targets.  Auro Pharma buy call hit 1st target.  JSW Steel buy call hit both targets.  Allahabad bank sell call hit both targets.  Voltas hit both targets  Adani Enterprise hit target.  Lupin almost hit 2nd target.  Havells sell call hit both targets.
  3. 3. BHARTI AIRTEL FUTURES – RISING WEDGE SELL BELOW 328.45 FOR TARGETS 327/325 SL 330.50 BUY ABOVE 250 FOR TARGETS OF 265/285 SL 235 Bharti Airtel sell we recommended executed today. It made a low of 327.65 near to our 1st target 327 Currently trading at cost at 328.50 Investors’ are advised to hold the position with recommended SL Targets are 327/325 and SL is recommended at 330.50 Bharti Airtel is making Rising wedge on hourly chart
  4. 4. AURO PHARMA FUTURES– DOUBLE TOP SELL BELOW 200 FOR TARGETS 198/195 SL 202 Sell Auro Pharma future below 200 Auro Pharma is making Double top on hourly chart Currently trading at 202.70 Investors’ are advised to sell below 200 for targets 198/195 SL is recommended at 367.50 Auro Pharma is having strong support at 200.50 and the call may take time in execution.
  5. 5. DisclaimerThe information and view in this report, our website & all the service we provideare believed to be reliable, but we do not accept any responsibility (or liability) forerrors of fact or opinion. Users have the right to choose the product/s that suitsthem the most.Sincere efforts have been made to present the right investment perspective. Theinformation contained herein is based on analysis and up on sources that weconsider reliable.This material is for personal information and based upon it & takes noresponsibilityThe information given herein should be treated as only factor, while makinginvestment decision. The report does not provide individually tailor-madeinvestment advice. Epic research recommends that investors independentlyevaluate particular investments and strategies, and encourages investors to seekthe advice of a financial adviser. Epic research shall not be responsible for anytransaction conducted based on the information given in this report, which is inviolation of rules and regulations of NSE and BSE.The share price projections shown are not necessarily indicative of future priceperformance. The information herein, together with all estimates and forecasts, canchange without notice. Analyst or any person related to epic research might beholding positions in the stocks recommended. It is understood that anyone who isbrowsing through the site has done so at his free will and does not read any viewsexpressed as a recommendation for which either the site or its owners oranyone can be held responsible for . Any surfing and reading of the information isthe acceptance of this disclaimer.All Rights Reserved. Investment in equity & bullion market has its own risks.We, however, do not vouch for the accuracy or the completeness thereof. we are notresponsible for any loss incurred whatsoever for any financial profits or losswhich may arise from the recommendations above epic research does not purportto be an invitation or an offer to buy or sell any financial instrument. Our Clients(Paid Or Unpaid), Any third party or anyone else have no rights to forward orshare our calls or SMS or Report or Any other information provided by us to/withanyone which is related directly or indirectly with them. If found so, then SeriousLegal Actions can be taken.